How does mazdutide compare to semaglutide and tirzepatide?

All three agents sit in the incretin class, but they are built on different receptor combinations and stand at very different points on the approval map. Semaglutide targets GLP-1 alone, tirzepatide targets GIP and GLP-1, and mazdutide targets GLP-1 and glucagon; only the first two carry marketing authorization in the United States and the European Union, while mazdutide's approvals are held in China. The honest bottom line is that comparative evidence is thin: one phase 3 head-to-head trial has been reported against semaglutide, none against tirzepatide, so nearly every cross-agent statement in circulation is an indirect comparison drawn from separate trials.

Which hormone receptors does each of these three agents activate, and why does that difference matter?

The receptor map separates these molecules more cleanly than any efficacy headline does. GLP-1 and GIP activity operate on the intake side of the energy equation, reducing how much a person eats, while glucagon receptor activation adds a spending-side mechanism that raises energy expenditure and mobilizes hepatic fat. More receptor targets is not automatically better, since each addition changes the risk profile alongside the benefit profile.

• Semaglutide, single target: GLP-1 receptor; glucose-dependent insulin secretion, slowed gastric emptying, central appetite suppression.
• Tirzepatide, dual target: GIP and GLP-1; the GIP arm is thought to add adipose nutrient handling and blunt some nausea burden.
• Mazdutide, dual target: GLP-1 and glucagon, built on the oxyntomodulin scaffold rather than an engineered GLP-1 analogue.
• Shared engineering: All three use fatty acid modification and albumin binding to support once-weekly subcutaneous dosing.

What weight reduction has each agent produced in its own registrational trials?

Reading these figures correctly means holding the trial designs side by side rather than lining up the headlines. The programs differ in duration, in baseline body weight, and in whether a reported number is total change from baseline or the placebo-adjusted difference, and those three variables alone can move a percentage several points. One finding holds across every program regardless of design: weight regain is the expected pattern after discontinuation, so these agents behave as chronic therapies rather than finite courses.

Why can trial results for these three agents not be compared directly?

Head-to-head design randomizes the same population, at the same sites, over the same duration, with the same endpoints and the same background care, which is the only way to isolate the drug as the variable. Cross-trial comparison discards that control, and the mazdutide obesity program differs from the semaglutide and tirzepatide programs on baseline weight, trial length, titration schedule, and the intensity of the diet and exercise counseling layered underneath. The evidence available on these three agents falls into three tiers, and they carry very different weight.

How do glycemic outcomes such as A1C reduction differ across the three agents?

On glycemic control the three agents sit closer together than the weight figures suggest, because A1C reduction compresses once a drug is potent enough to bring most participants near target. A well-established statistical feature applies across all three programs: the higher the baseline A1C, the larger the absolute reduction reported, so a trial enrolling participants at 8.5 percent will show bigger drops than one enrolling at 7.8 percent regardless of drug potency.

How do the reported side effect and tolerability profiles differ?

Gastrointestinal events dominate the safety picture across all three programs and are the main reason participants stopped treatment. Nausea, vomiting, diarrhea, constipation, and reduced appetite were concentrated in the dose escalation phase and were generally mild to moderate and transient, with discontinuation rates attributable to adverse events sitting broadly in the single digits to low teens. The one profile difference that traces to mazdutide's distinct receptor arm is cardiac rather than gastrointestinal.

• Resting heart rate: Mazdutide's phase 3 obesity trial reported a mean rise of 2.6 beats per minute at week 48.
• Class labeling: Heart rate increase appears as a labeled warning for approved GLP-1 agents as well.
• Hepatic and lipid markers: Transaminases, liver fat content, and blood lipids fell rather than rose in that trial.
• Class contraindications: Personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2.
• Body composition: Rapid reduction of this magnitude carries lean mass loss alongside fat mass loss.

What does adding glucagon receptor activity do that GLP-1 or GIP activity does not?

Glucagon is usually introduced as the hormone that raises blood glucose, and that framing understates it. Glucagon also increases resting energy expenditure, promotes lipolysis, stimulates hepatic fatty acid oxidation, and contributes to satiety signaling, which is why a GLP-1 and glucagon dual agonist attacks body weight from two directions at once. The design challenge is ratio, not presence.

How do dosing schedules, titration timelines, and maximum doses differ?

All three are once-weekly subcutaneous injections that begin low and step upward on a fixed schedule, but the milligram numbers are not comparable between molecules. Strength reflects each peptide's own receptor affinity and clearance rather than any shared scale, so reading mazdutide's 6 mg as smaller than tirzepatide's 15 mg says nothing about relative effect.

1. Starting dose: Semaglutide begins at 0.25 mg weekly, tirzepatide at 2.5 mg weekly, mazdutide at a correspondingly low step.
2. Escalation interval: Each approved schedule steps upward at roughly four-week intervals to let the gastrointestinal system adapt.
3. Maintenance: Semaglutide reaches 2.4 mg for chronic weight management; tirzepatide offers 5, 10, or 15 mg; mazdutide is approved in China at 4 mg and 6 mg for both indications.
4. Tolerability holds: Standard practice when a patient struggles at a step is holding the tolerated dose longer rather than advancing.

How does regulatory approval status differ by country for each agent?

Approval status is the sharpest practical dividing line between mazdutide and the other two, and it is routinely lost behind the efficacy comparisons. Where a drug is unapproved, it has not passed that regulator's own benefit and risk assessment, there is no approved labeling, no manufacturing oversight of the product a patient might obtain, and no established pathway for legitimate prescription or dispensing.

• Semaglutide and tirzepatide: Approved across the United States, European Union, United Kingdom, Japan, and China.
• Mazdutide: Approved by China's National Medical Products Administration for chronic weight management and type 2 diabetes.
• Mazdutide outside China: No marketing authorization in the United States, the European Union, or the United Kingdom.
• Timeline driver: Regulators expect data relevant to their own populations, so a domestic-first filing reaches approval years ahead of any global one.

How do cost, supply, and practical access compare between the three?

Cost in this class behaves less like a drug price and more like a coverage question. United States list prices for semaglutide and tirzepatide have sat in the range of roughly one thousand to fourteen hundred dollars per month before discounts, while European and Asian pricing runs generally lower under different national pricing negotiation systems. Because weight regain follows discontinuation, the relevant economic figure is annual and multi-year cost rather than the monthly sticker.